Your browser doesn't support javascript.
loading
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
Niemeijer, A N; Leung, D; Huisman, M C; Bahce, I; Hoekstra, O S; van Dongen, G A M S; Boellaard, R; Du, S; Hayes, W; Smith, R; Windhorst, A D; Hendrikse, N H; Poot, A; Vugts, D J; Thunnissen, E; Morin, P; Lipovsek, D; Donnelly, D J; Bonacorsi, S J; Velasquez, L M; de Gruijl, T D; Smit, E F; de Langen, A J.
Afiliação
  • Niemeijer AN; Department of Pulmonary Diseases, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
  • Leung D; Bristol-Myers Squibb Research and Development, Route 206 & Province Line Rd., Princeton, NJ, 08543, USA.
  • Huisman MC; Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
  • Bahce I; Department of Pulmonary Diseases, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
  • Hoekstra OS; Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
  • van Dongen GAMS; Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
  • Boellaard R; Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
  • Du S; Bristol-Myers Squibb Research and Development, Route 206 & Province Line Rd., Princeton, NJ, 08543, USA.
  • Hayes W; Bristol-Myers Squibb Research and Development, Route 206 & Province Line Rd., Princeton, NJ, 08543, USA.
  • Smith R; Bristol-Myers Squibb Research and Development, Route 206 & Province Line Rd., Princeton, NJ, 08543, USA.
  • Windhorst AD; Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
  • Hendrikse NH; Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
  • Poot A; Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
  • Vugts DJ; Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
  • Thunnissen E; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
  • Morin P; Bristol-Myers Squibb Research and Development, Route 206 & Province Line Rd., Princeton, NJ, 08543, USA.
  • Lipovsek D; Bristol-Myers Squibb Research and Development, Route 206 & Province Line Rd., Princeton, NJ, 08543, USA.
  • Donnelly DJ; Bristol-Myers Squibb Research and Development, Route 206 & Province Line Rd., Princeton, NJ, 08543, USA.
  • Bonacorsi SJ; Bristol-Myers Squibb Research and Development, Route 206 & Province Line Rd., Princeton, NJ, 08543, USA.
  • Velasquez LM; Bristol-Myers Squibb Research and Development, Route 206 & Province Line Rd., Princeton, NJ, 08543, USA.
  • de Gruijl TD; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
  • Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 2, 1066 CX, Amsterdam, The Netherlands.
  • de Langen AJ; Department of Pulmonary Diseases, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. j.d.langen@nki.nl.
Nat Commun ; 9(1): 4664, 2018 11 07.
Article em En | MEDLINE | ID: mdl-30405135
ABSTRACT
PD-L1 immunohistochemistry correlates only moderately with patient survival and response to PD-(L)1 treatment. Heterogeneity of tumor PD-L1 expression might limit the predictive value of small biopsies. Here we show that tumor PD-L1 and PD-1 expression can be quantified non-invasively using PET-CT in patients with non-small-cell lung cancer. Whole body PD-(L)1 PET-CT reveals significant tumor tracer uptake heterogeneity both between patients, as well as within patients between different tumor lesions.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article